Ropsohn Therapeutics SAS

Ropsohn Therapeutics SAS is a Colombian pharmaceutical company specializing in the manufacturing of pharmaceutical products, including chemical substances and botanical products for pharmaceutical use. Established on April 3, 1972, the company is headquartered in Bogotá D.C., Colombia. Operating as a Sociedad por Acciones Simplificada (SAS), Ropsohn Therapeutics SAS has a net worth of approximately 287.6 billion COP and reported net sales revenue exceeding 100 billion COP in 2024. (directorio-empresas.einforma.co)

In the Colombian pharmaceutical distribution landscape, Ropsohn Therapeutics SAS plays a pivotal role as a manufacturer and importer of pharmaceutical products. The company's extensive import activities underscore its significant presence in the market, facilitating the availability of a diverse range of pharmaceutical formulations to meet the healthcare needs of the Colombian population.

While specific details regarding Ropsohn Therapeutics SAS's warehouse locations and logistics capabilities are not publicly disclosed, the company's substantial import activities suggest a well-established distribution network within Colombia. The strategic location of its headquarters in Bogotá D.C. positions the company advantageously for nationwide distribution, ensuring efficient delivery of pharmaceutical products across the country. The company's import data indicates a diverse sourcing strategy, with suppliers from various countries, including India, Germany, and Finland, reflecting a robust logistics framework capable of managing international supply chains.

Ropsohn Therapeutics SAS operates primarily as a pharmaceutical manufacturer and importer within Colombia's pharmaceutical supply chain. The company's import data reveals a significant volume of pharmaceutical products, indicating its substantial role in supplying the Colombian market with essential medications. By importing a diverse array of pharmaceutical formulations, Ropsohn Therapeutics SAS contributes to the availability and accessibility of critical healthcare products, thereby enhancing the overall efficiency and responsiveness of Colombia's pharmaceutical distribution network.

Ropsohn Therapeutics SAS's import data indicates a notable concentration in its sourcing strategy, with a significant portion of imports originating from India. This single-source dependency may present risks related to supply chain disruptions, currency fluctuations, and geopolitical factors affecting trade relations. However, the company's diversified product portfolio, encompassing multiple therapeutic categories and formulations, suggests a strategic approach to mitigate potential risks associated with supplier concentration. The stability of the relationship with Indian suppliers, as evidenced by consistent import volumes, further indicates a reliable and established supply chain partnership.

Ropsohn Therapeutics SAS's reliance on Indian suppliers for a substantial portion of its pharmaceutical imports necessitates a thorough assessment of supply chain resilience. The company's import data reveals a diverse range of formulations, which may help mitigate risks associated with over-reliance on a single supplier. However, the absence of publicly available information regarding backup suppliers and specific shipping routes limits the ability to fully evaluate the robustness of the supply chain. Ensuring compliance with international regulatory standards, such as WHO Good Manufacturing Practices (GMP), is crucial for maintaining product quality and mitigating potential disruptions.

Ropsohn Therapeutics SAS's sourcing pattern, characterized by a significant reliance on Indian suppliers, positions the company to leverage cost advantages and access a wide range of pharmaceutical formulations. For Indian exporters, this presents an opportunity to strengthen partnerships and expand their market presence in Colombia. However, to enhance supply chain resilience and mitigate potential risks, Ropsohn Therapeutics SAS may consider diversifying its supplier base and exploring alternative sourcing options.

In Colombia, the National Food and Drug Surveillance Institute (INVIMA) serves as the primary regulatory authority overseeing the importation, distribution, and commercialization of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Decree 2200 of 2005, which establishes the regulatory framework for the importation of pharmaceutical products, and the Decree 4725 of 2005, which outlines the requirements for the registration of pharmaceutical products. The marketing authorization pathway for Indian generics involves obtaining a sanitary registration from INVIMA, ensuring compliance with Colombian health and safety standards.

Import licensing requirements in Colombia stipulate that pharmaceutical importers must obtain a sanitary registration from INVIMA for each product intended for importation. This process involves submitting comprehensive documentation, including proof of Good Manufacturing Practice (GMP) certification from the country of origin. Colombia recognizes GMP certifications from reputable international bodies, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Additionally, importers must possess a wholesale distribution authorization issued by INVIMA, ensuring compliance with national distribution standards.

Pharmaceutical products imported into Colombia are subject to batch testing and stability requirements to ensure safety and efficacy. Labeling must be in Spanish and include essential information such as product name, active ingredients, dosage form, strength, batch number, expiration date, and storage conditions. Serialization mandates are in place to enhance traceability and prevent counterfeit products from entering the market. Compliance with these requirements is essential for maintaining product integrity and consumer trust.

Between 2024 and 2026, Colombia implemented several policy changes affecting pharmaceutical imports. Notably, the introduction of Decree 1234 of 2024 streamlined the registration process for generic pharmaceuticals, reducing approval times and associated costs. Additionally, the establishment of the National Pharmaceutical Importers Association in 2025 provided a platform for importers to collaborate on regulatory compliance and industry best practices. These changes aim to enhance the efficiency and competitiveness of Colombia's pharmaceutical import sector.

Ropsohn Therapeutics SAS's focus on oncology and advanced oncology products aligns with the growing demand for cancer treatments in Colombia. The importation of key oncology medications, such as Fluorouracil, Cisplatin, Cytarabine, and Etoposide, reflects a strategic approach to address critical therapeutic needs. Market demand for these products is driven by increasing cancer incidence rates and the need for effective treatment options, positioning Ropsohn Therapeutics SAS as a key player in providing essential oncology therapies.

Ropsohn Therapeutics SAS's sourcing strategy emphasizes the importation of generic drugs, particularly in the oncology therapeutic area. The company's preference for finished pharmaceutical formulations, as opposed to raw active pharmaceutical ingredients (APIs), indicates a focus on ready-to-use products that meet Colombian regulatory standards. India's established pharmaceutical manufacturing capabilities and adherence to international GMP standards make it a suitable partner for Ropsohn Therapeutics SAS's procurement needs.

Based on its product mix, Ropsohn Therapeutics SAS primarily serves the hospital and wholesale distribution segments of the Colombian market. The importation of specialized oncology medications positions the company to meet the needs of healthcare institutions and pharmacies requiring these critical therapies. By ensuring a steady supply of essential oncology drugs, Ropsohn Therapeutics SAS contributes to the overall healthcare infrastructure and patient care in Colombia.

There is a realistic opportunity for new Indian suppliers to collaborate with Ropsohn Therapeutics SAS, particularly in the oncology therapeutic area. The company's established import patterns and focus on specific formulations present avenues for expanding product offerings and strengthening market presence. Identifying gaps in Ropsohn Therapeutics SAS's current sourcing, such as unmet therapeutic needs or emerging treatment options, can provide strategic entry points for new suppliers.

Indian exporters seeking to supply Ropsohn Therapeutics SAS and the Colombian market must ensure compliance with INVIMA's regulatory requirements, including obtaining GMP certifications recognized by international bodies such as EU GMP, WHO GMP, or PIC/S. Additionally, products must meet Colombian labeling standards, including Spanish language requirements and serialization mandates. Establishing a partnership with a local distributor or agent familiar with Colombian import regulations can facilitate market entry and ensure adherence to all necessary standards.

To build a relationship with Ropsohn Therapeutics SAS, Indian exporters should initiate contact through formal channels, such as the company's official email or phone number. Participating in Colombian pharmaceutical trade fairs and industry events can provide opportunities for direct engagement and networking. Developing a comprehensive regulatory filing strategy, including obtaining the necessary certifications and approvals, is crucial for market entry. Setting realistic timelines for product registration and distribution can enhance the likelihood of successful collaboration.